Everything below concerns Stenabolic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
American kestrels in Canada and the northern United States typically migrate south in the winter, some of them converging with resident kestrels of smaller size in Mexico, sometimes going as far as Central America and the Caribbean. Birds that breed south of about 35° north latitude are usually year-round residents. Migration also depends on local weather conditions. American Kestrels breeding at lower latitudes – below 48ºN to be precise – arrive earlier after warmer springs, whereas birds from higher latitudes return to their breeding grounds at the same time each year. These patterns suggest that short-distance migrants are better able to cope with climate change. Wintering kestrels' choice of habitat varies by sex. Females are found in open areas more often than males during the non-breeding season. A common explanation for this behavior is that the larger females who are bigger than the males arrive at the preferred habitat first and exclude males from their territory. The American kestrel is not long-lived, with a lifespan of <5 years for wild birds. The oldest banded wild bird was 11 years and 7 months, while captive kestrels can live up to 14–17 years. In a study, humans accounted for 43.2% of 1,355 reported deaths, which included direct killing and roadkills, while predation (including by larger birds of prey) accounted for 2.8%. This statistic is likely biased, however, as reported deaths are usually found near or in areas populated by humans.
== Uses == One use for the compound lead(II) iodate is the volumetric determination of lead content in ore. The determination of lead content in a sample of ore begins with the precipitation and separation of lead as a sulfate. The solution of this lead sulfate product is then slightly acidified and the lead is precipitated out as lead(II) iodate out by adding potassium iodate. Lead(II) iodate can then be titrated in the presence of hydrochloric acid and chloroform to indicate the exact amount of lead that was dissolved from the original ore sample. In this chemical process lead(II) iodate is used to isolate the lead found in a sample of ore from other chemicals present so that it can be studied and quantitated effectively.
== Mechanism of action, metabolic end-products, and metabolic rate == [18F]FDG, as a glucose analog, is taken up by high-glucose-using cells such as brain, brown adipocytes, kidney, and cancer cells, where phosphorylation prevents the glucose from being released again from the cell, once it has been absorbed. The 2-hydroxyl group (–OH) in normal glucose is needed for further glycolysis (metabolism of glucose by splitting it), but [18F]FDG is missing this 2-hydroxyl. Thus, in common with its sister molecule 2-deoxy-D-glucose, FDG cannot be further metabolized in cells. The [18F]FDG-6-phosphate formed when [18F]FDG enters the cell cannot exit the cell before radioactive decay. As a result, the distribution of [18F]FDG is a good reflection of the distribution of glucose uptake and phosphorylation by cells in the body. The fluorine in [18F]FDG decays radioactively via beta-decay to 18O−. After picking up a proton H+ from a hydronium ion in its aqueous environment, the molecule becomes glucose-6-phosphate labeled with harmless nonradioactive "heavy oxygen" in the hydroxyl at the C-2 position. The new presence of a 2-hydroxyl now allows it to be metabolized normally in the same way as ordinary glucose, producing non-radioactive end-products. Although in theory all [18F]FDG is metabolized as above with a radioactivity elimination half-life of 110 minutes (the same as that of fluorine-18), clinical studies have shown that the radioactivity of [18F]FDG partitions into two major fractions.
MDO-NPA (10,11-methylenedioxy-N-n-propylnoraporphine) is a synthetic aporphine derivative used as a research tool in neuropharmacology. It was developed as a methylenedioxy prodrug of N-n-propylnorapomorphine (NPA). A noteworthy advantage that the MDO-NPA congener has over NPA and apomorphine is that MDO-NPA has a high oral bioavailability, whereas the other two do not and must be delivered via subcutaneous injection or intraperitoneally.
Sources: en.wikipedia.org
== Uses == Rhodiola extracts have been used historically in medicine throughout Europe. A number of species are grown as ornamentals, but growing them is difficult outside their native subarctic and alpine climates. In traditional Chinese medicine, extracts of Rhodiola plants are used for conditions such as fatigue and altitude sickness. Currently, there is insufficient evidence to determine if Rhodiola is effective for any health condition.
=== Peptide === Ghrelin (Lenomorelin, GHRL) GHRP-1 GHRP-2 (Pralmorelin; GHRP Kaken 100; GHRP-2; KP-102, GPA-748, WAY-GPA-748) GHRP-3 GHRP-4 GHRP-5 GHRP-6 (SKF-110679) Alexamorelin Examorelin (hexarelin; EP-23905, MF-6003) Ipamorelin (NNC 26-0161) Relamorelin (RM-131, BIM-28131, BIM-28163) Tabimorelin (NN-703)
SrSO4 + 2 C → SrS + 2 CO2 About 300,000 tons are processed in this way annually. The metal is produced commercially by reducing strontium oxide with aluminium. The strontium is distilled from the mixture. Strontium metal can also be prepared on a small scale by electrolysis of a solution of strontium chloride in molten potassium chloride:
ISBN 978-0-87220-923-7. Powell, Anton (1990). Euripides, Women and Sexuality. Routledge Press. ISBN 0-415-01025-X. Pucci, Pietro. "Survival in the Holy Garden." The Violence of Pity In Euripides’ “Medea,” vol. 41, Cornell University Press, 1980, pp. 91–130. JSTOR, http://www.jstor.org/stable/10.7591/j.cttq44w0.6. Accessed 27 Mar. 2023. Rabinowitz, Nancy S. (1993). Anxiety Veiled: Euripides and the Traffic in Women. Cornell University Press. ISBN 0-8014-8091-4. Saïd, Suzanne (2002). "Greeks and Barbarians in Euripides' Tragedies: The End of Differences?". In Harrison, Thomas (ed.). Greeks and Barbarians. Translated by Antonia Nevill. Taylor & Francis. ISBN 0-415-93959-3. Sommerstein, Alan (2002). Greek Drama and Dramatists. Routledge Press. ISBN 0-203-42498-0. ISBN 978-0-203-42498-8 Tessitore, Aristide. "Euripides’ ‘Medea’ and the Problem of Spiritedness." The Review of Politics, vol. 53, no. 4, 1991, pp. 587–601. JSTOR, JSTOR 1407307. Accessed 27 Apr. 2023. Tigani, Francesco (2010), Rappresentare Medea. Dal mito al nichilismo, Aracne. ISBN 978-88-548-3256-5 Mossman, Judith (2011). Medea: Introduction, Translation and Commentary. Warminster: Aris & Phillips. ISBN 978-0-856-68788-4.
In late 1998, a number of confidential Microsoft documents later dubbed the Halloween documents were leaked to Eric S. Raymond, an activist in the open-source software movement, who published and commented on them online. The documents revealed that internally Microsoft viewed free and open-source software such as Linux as technologically competitive and a major threat for Microsoft's dominance in the market, and they discussed strategies to combat them. The discovery caused a public controversy. The documents were also used as evidence in several court cases. Nintendo's crossover fighting video game series Super Smash Bros. has a history of having unconfirmed content leaked. Every game since, including 2008's Super Smash Bros. Brawl has been affected by leaks in some form: Super Smash Bros. Brawl for the Wii was leaked by a video on the Japanese language wii.com website, revealing unconfirmed playable characters on January 28, 2008 (three days before the game's Japanese release). Super Smash Bros. for Nintendo 3DS and Wii U was afflicted in August 2014 by the "ESRB leak", where many screenshots and limited video footage of the 3DS version were leaked by a supposed member of the ESRB. The leak gained traction very quickly due to the screenshots mostly containing elements that the game ratings board would be interested in, such as trophies of suggestively-dressed female characters (some of which were later found to be edited or cut altogether in the final game). Super Smash Bros.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.